Trials / Completed
CompletedNCT05118750
ALTO-300 in Depression
An Open-label Study of ALTO-300 in Adults With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Alto Neuroscience · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALTO-300 oral (PO) tablet | One tablet daily |
Timeline
- Start date
- 2021-12-13
- Primary completion
- 2023-05-05
- Completion
- 2023-05-09
- First posted
- 2021-11-12
- Last updated
- 2024-04-30
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05118750. Inclusion in this directory is not an endorsement.